Lyxumia | ASweetLife

Sanofi’s Lyxumia Approved for Type 2 Diabetes Treatment in Japan

Japan's Ministry of Health, Labor and Welfare (MHLW) approved the manufacturing and distribution of Sanofi's new type 2 diabetes treatment, Lyxumia (lixisenatide) in Japan. Lyxumia, the first once daily prandial GLP-1 receptor agonist (RA), is also the first GLP-1 RA approved in Japan...

FDA to Review NDA for Lixisenatide, Sanofi’s New Type 2 Diabetes Therapy

The FDA has accepted Sanofi's New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes, for review. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union.

Lyxumia, Sanofi’s Type 2 Diabetes Treatment, Approved in EU

The European Commission has granted Marketing Authorisation in Europe for Sanofi's new type 2 diabetes treatment, Lyxumia (lixisenatide). Lyxumia is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal.

Sanofi Presents New Data on Lixisenatide, an Investigational GLP-1 Agonist, for Type 2 Diabetes

Sanofi has presented data from two studies demonstrating Lyxumia (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents (OADs), significantly reduced HbA1c levels...

Positive Results for Sanofi’s Lyxumia in Treatment of Type 2 Diabetes

Sanofi announced positive results from the Gel Duo 1 study of it's investigational GLP-1 agonist, Lyxumia (lixisenatide) in the treatment of type 2 diabetes patients. The results show that patients with type 2 diabetes uncontrolled on oral anti-diabetics (OADs) – mainly metformin - significantly reduced their HbA1c levels when...

Sanofi Releases More Results from Type 2 Diabetes Drug Lyxumia (lixisenatide) Study

Sanofi has released additional positive results from the global GetGoal Phase III development program with Lyxumia (lixisenatide) for the treatment of type 2 diabetes. Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist, was invented by Zealand Pharma and global rights are with Sanofi...

Sanofi-aventis Announces Positive Results for Lixisenatide

Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from...

Positive Results for New Sanofi-aventis Type 2 Diabetes Drug

Sanofi-aventis announced that the GetGoal-X Phase 3 study of lixisenatide, a once-daily GLP-1 receptor agonist, has achieved primary efficacy endpoint. Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus.

Sanofi-aventis’ Once-Daily Type 2 Diabetes Drug Lixisenatide Shows Significant Improvement in Glucose Control

Sanofi-aventis announced the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden...

Sanofi-Aventis Diabetes Monotherapy Meets Phase III Study Endpoint Successfully

Sanofi-aventis announced the results of the first placebo-controlled study of the GetGoal Phase III clinical trial program of lixisenatide (AVE0010), a once-daily GLP-1 agonist developed for patients with type 2 diabetes. The 12-week study involved 361 patients with type 2 diabetes not currently receiving glucose-lowering therapy and with HbA1c between 7 and 10%...